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Abstract
We have developed a new biodegradable scaffold that does not require any cell seeding to create an in-situ tissue-
engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-
mm tubular biodegradable scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone
copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into
the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia.
The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an
intravascular ultrasound imaging system was about 90% of the native IVC after 1 month. Angiography of the iTEV after 2
years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of
0.5160.19 mmHg. The length of the iTEV at 2 years had increased by 0.4860.15 cm compared with the length of the
original scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification.
Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with
the native IVC. We concluded that the findings shown above provide direct evidence that the new scaffold can be useful for
cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had
adapted its shape to the needs of the living body. Therefore, this scaffold would be applicable for pediatric cardiovascular
surgery involving biocompatible materials.
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Introduction
The use of foreign materials is necessary to repair complex heart
defects. However, the materials that are commonly used are not
biocompatible with the host tissue and do not have the ability to
change their shape as the host grows. In addition, long-term
studies of the efficacy of these materials have revealed several
material-related failures, such as stenosis, thromboembolization,
and calcium deposition. To solve these problems and to improve
the treatment of children who require implantation of materials
possessing growth potential, we have been pursuing the develop-
ment of optimal biocompatible materials.
We previously reported the advantages of using biodegradable
scaffolds seeded with autologous cells as tissue-engineered vascular
autografts (TEVAs) in canine models [1,2,3] and in a human
clinical study [1,4,5]. The key benefit of utilizing such scaffolds is
that the scaffold degrades in vivo, thereby avoiding the long-term
presence of foreign materials, while the seeded cells proliferate to
form new tissue [2,6]. We also reported that the seeded cells are
able to differentiate into cells that compose the vessel wall and may
act as cytokine producers [6]. However, the contributions of the
seeded cells remain uncertain [6]. There was no graft-related
mortality and no evidence of aneurysm formation, graft rupture,
graft infection, or ectopic calcification in the late-term results for
TEVAs in 25 patients (mean follow-up, 5.8 years) [4]. However, 4
of the 25 patients had graft stenosis and underwent successful
percutaneous angioplasty [4]. To overcome the graft stenosis of
TEVAs, we explored a new scaffold without cell seeding, and
achieved acceptable long-term results as evaluated by new
techniques involving an intravascular ultrasound imaging system.
This new scaffold can be implanted by a simple cost-effective
procedure, because no cell preparation and seeding are necessary.
In the present study, we evaluated the long-term outcomes,
usefulness, and basic characteristics of an in-situ tissue-engineering
vasculature (iTEV) constructed through cell-free and direct
implantation of the new biodegradable scaffold in a canine model.
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Overview, the mechanical properties and degradation of
a newly developed biodegradable scaffold
Shown as an overview in Figure 1A, this scaffold degraded by
hydrolysis after implantation. Changes over time in the scaffold’s
mechanical strength and molecular weight in vivo are shown in
Figures 1B and 1C. Most of the scaffold’s strength was lost within a
month and molecular weight decreased within 6 months,
suggesting that the scaffold was almost entirely degraded and
resorbed into the body during the 6-month implantation.
Biomechanical changes of biodegradable scaffolds
The mechanical properties of biodegradable scaffolds in vitro
were evaluated by soaking in phosphate buffered saline (PBS) at
37uC and testing with a tensiometer, and it was found that the
scaffold degraded by hydrolysis, losing half of its tensile strength in
2–3 weeks and entirely within 10 weeks. The scaffold’s tensile
strength per cm width at 0, 1, 2, 3, 4, 6, and 9 weeks in vitro were
9.3, 6.9, 5.3, 2.1, 1.2, 0.4, and 0.1 N, respectively (Fig. 1B). The
scaffold’s molecular weight changes under these conditions
decreased with time, decreasing by 0, 1, 2, 4, 6, 8, 13, 20, and
25 weeks to 194267, 163566, 124383, 82709, 51737, 32867, 8655,
6190, and 4387 daltons, respectively (Fig. 1C).
Macroscopic and histological findings of iTEV
All animals remained alive and well without any serious
complications until euthanasia at 1(n=3), 2.5(n=3), and 24
months (n=7). Vessel-like iTEVs were recovered at 2 years by
dissection and examined (Fig. 2A, black arrow, distance between
suture sites at implantation). Internal iTEV sections showed
completely endothelialized surfaces and thin vessel walls (Fig. 2B).
Implanted scaffold lengths and iTEVs after explantation from
individual dogs showed that all iTEVs increased in length over the
2-year period, ranging from 0.1 to 1.0 cm (mean 6SEM,
0.4860.15 cm, Fig. 2C). When explanted at 2 years, the mean
diameters of iTEVs sited close to the diaphragm and the atrium
were 11.860.7 and 8.760.8 mm, respectively (Fig. 2D). All iTEV
diameters increased during the 2-year period compared with the
initial implanted 8 mm tubular-shaped scaffold. The iTEV
sections at 1 month showed the presence of P(GA/CL)
monofilaments (Fig. 2E), but they appeared to be resorbed in
iTEV sections at 2.5 months (Fig. 2F). Immunohistological study
revealed endothelialization (factor VIII-positive) and smooth
muscle cell (alpha smooth muscle cell actin [ASMA]-positive)
proliferation in iTEV sections at 1 and 2.5 months (Fig.2G). The
components of the four basic vascular layers, endothelial cells
(Factor VIII-positive), smooth muscle cells (ASMA-positive), elastic
fibers, and collagen fibers, were observed in iTEV sections at 2
years (Fig. 3A–E); no calcified lesions were observed (Fig. 3F). As
the biodegradable materials were entirely degraded within 6
months, these findings suggested that the application of P(GA/CL)
monofilaments to the scaffold did not cause calcification. A
comparison of the wall thicknesses of native inferior vena cava
(IVC) and iTEV showed that native IVC and iTEV walls were
0.3160.01 and 0.2960.01 mm thick, respectively, and were not
significantly different (p=0.511, Fig. 3G).
Angiographic and biomechanical findings using the IVUS
Seven animals were evaluated by angiography while in a right
lateral position and an intravascular ultrasound imaging system
(IVUS) employed in a catheter laboratory to confirm the iTEV
characteristics, pressure gradient, and elastic modulus. Time-
course changes of the smallest internal diameters of iTEVs
measured by angiography revealed that the iTEV diameters at
1, 2.5, 6, 12, and 24 months were 3.5560.62, 4.0661.12,
5.2861.22, 6.9261.75, and 7.9861.86 mm, respectively (Fig. 4A).
The smallest internal diameters iTEVs increased the most in
diameter during the 2-year period (Kruskal–Walis tests; p,0.001).
It should be noted that diameter decreased during neointimal
growth on the scaffold, the tissue remodeled within 6 months into
native tissues with concurrent material degradation, and the
internal diameter tended to increase and adapt its shape as the
living body required. The smallest internal diameter of the dog
native IVCs (6.8160.52; n=6) showed remarkable differences
from those of the 1, 2.5, and 6-month iTEV, but no significant
differences from the 12 and 24-month iTEVs (Mann–Whitney U
test; native IVCs versus 1- or 2.5-month iTEVs, p,0.001, native
IVCs versus 6-month iTEVs, p,0.05). Angiogram data showed
some feature changes during the iTEV remodeling and scaffold
degradation processes (Fig. 4B), and following the angiograms,
pressure studies were performed using a Millar pressure catheter
system, which showed that the pressure gradient between the
iTEV proximal and distal sites was 0.5160.19 mmHg at 24
months (Fig. 4C).
IVUS images showing iTEV changes over time indicated that
the scaffold was located between the neointima and adventitia
during tissue development (Fig. 5, 1, and 2.5 months).
Data for the pressure-to-strain (P-S) loops of the iTEV and
native IVC at 2 years and of a control (scaffold itself) showed that
the ratios of the elastic modulus of the iTEV to native IVC at 0
(control), 1, 2.5, 6, 12, and 24 months were 7.360.5, 2.360.7,
1.160.2, 1.060.2, 1.460.2, and 1.160.2, respectively (Fig. 6).
The elastic modulus of the iTEV decreased over time and was
almost the same as the native IVC after 2.5 months. Also, there
were significant differences between the control scaffold and the
Figure 1. Overview of the new biodegradable scaffold and its degradation. A, biodegradable scaffold 8 mm in diameter; bar, 1 cm. B,
tensile strength changes in biodegradable scaffolds in vitro; scaffold strength diminished remarkably over 4 weeks. C, Mw changes in scaffold
immersed in 37uC PBS; gradual hydrolysis decreased Mw.
doi:10.1371/journal.pone.0035760.g001
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1, 2.5, 6, 12, and 24 months.
Finally, elastic moduli data were used to calculate iTEV
regeneration scores at 1, 2.5, 6, 12, and 24 months and found to be
90.362.9%, 93.861.7%, 95.861.1%, 93.760.8%, and
92.762.5%, respectively (Fig. 6C). There were no significant
differences among these samples (p=0.836).
Biochemical findings
There were no significant differences in the protein content of
iTEVs and native IVCs at 2 years, with the densitometry ratios of
Figure 2. Macroscopic views, changes of length, diameter, and histological findings of iTEV. A, macroscopic view of iTEV appearance at 2
years when the dog’s chest was reopened; black double-headed arrow, distance between two iTEV suture lines, representing iTEV length. B,
macroscopic view of iTEV internal surface; smooth endothelialized surface and thin vessel wall; bar, 1 cm. C, implanted scaffold lengths and explanted
iTEVs (n=7) at 2 years after implantation; scaffold length data when implanted and iTEVs when explanted expressed as box-whisker plot; each
individual length difference expressed as dot-to-dot. D, iTEV diameters at sites close to diaphragm and right atrium (n=7) at 2 years after
implantation; lines, lower, median, and upper quartile values; whiskers, extent of remaining data. E, iTEV histology at 1 month (Masson’s trichrome
staining); black arrows indicate P(GA/CL) monofilament remaining at 1 month after implantation; bar, 100 mm. F, iTEV histology at 2.5 months; P(GA/
CL) monofilament no longer present; bar, 100 mm. G, factor VIII positive and ASMA-positive cells expressed in iTEV at 1 and 2.5 months; bar, 100 mm.
doi:10.1371/journal.pone.0035760.g002
Figure 3. Histological results of an iTEV at 2 years. Representative iTEV histological sections: A, H&E staining, flattened cell monolayer lining
iTEV surface layer of endothelial cells. B, Masson’s trichrome staining, smooth muscle cells (red) and collagen fibers (blue). C, Victoria blue–van Gieson
staining, elastic fiber and smooth muscle cell proliferation; D and E, factor VIII and ASMA clearly visible, respectively. F, modified von Kossa staining,
no calcified lesions; bars, 100 mm. G, wall thickness of native IVC and iTEV at 2 yr (n=7 each) in histological samples; 10 sites for each sample; no
significant difference between wall thicknesses of native IVC and iTEV (p=0.511 by the Mann–Whitney U test); NS, not significant.
doi:10.1371/journal.pone.0035760.g003
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and 5.060.4, respectively (p=0.193) and the densitometry ratios
of ASMA protein to beta-actin in IVCs and iTEVs at 1.160.1 and
1.260.1, respectively (p=0.907, Fig. 7).
There were also no significant differences in the elastin,
hydroxyproline, and calcium contents between normal IVCs and
iTEVs (Fig. 8A–C), with elastin content of native IVCs and iTEVs
at 52.669.1 and 57.965.1 mg/g wet tissue weight, respectively
(p=0.615). Based on hydroxyproline concentration, the collagen
Figure 4. Changes of diameters, angiographic findings, and pressure gradient of iTEVs. A, smallest iTEV diameter changes from
angiographies at 1, 2.5, 6, 12, and 24 months after implantation; ***, p,0.001 and *, p,0.05 compared to native IVCs by the Mann–Whitney U test. B,
representative iTEV angiographies at 1, 2.5, 6, and 12 months after implantation; iTEV feature differences showing remodeling and tissue generation;
magnification ratio adjusted using sheath size; bar, 7Fr, ,2.33 mm; RA, right atrium. C, mean pressures at right atrium and distal liver (IVC); mean
pressure gradient between two sites (n=7 each); pressure gradient between iTEV proximal and distal sites, 0.5160.19 mmHg, when measured by
Millar pressure catheter system.
doi:10.1371/journal.pone.0035760.g004
Figure 5. IVUS images of an iTEV. Representative IVUS images of iTEV in diastole and systole phases taken immediately after implantation
(control) and at 1, 2.5, 6, 12, and 24 months; showing iTEV wall thickness and internal diameter changes and scaffold degradation; waves, venous
pressure measured by Millar pressure catheter system; white dots on waves, phase of venous pressure and iTEV wall motion; bar, 5 mm.
doi:10.1371/journal.pone.0035760.g005
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142619 mmol/g wet tissue weight, respectively (p=0.750). And
finally, the calcium content of native IVCs and iTEVs were
0.2160.05 and 0.2760.05 mg/g wet tissue weight, respectively
(p=0.165).
Discussion
In the present study, evaluation of the long-term results from
iTEVs, produced by tubular composite scaffold implantation
without cell seeding in a canine model, revealed their efficacy in
terms of patency and in their histological, biomechanical, and
biochemical similarities to native vessels. It was clearly demon-
strated that the morphology of the implanted biodegradable
scaffold was remodeled.
Previously here, clinical applications of tissue-engineered
vascular autographs (TEVAs) have been successful, using cultured
venous cell mixtures as a cell source with seeding onto a
biodegradable scaffold prior to implantation [1]. However, this
protocol proved difficult to manipulate, as bovine serum was
necessary and the cell preparation process took several weeks.
Thus, the procedure was altered to incorporate mononuclear bone
marrow cells (MN-BMCs) as the cell source, as they can be easily
prepared on the day of procedure [1]. MN-BMC-seeded TEVAs
have regenerated vessel-like structures with good results in animal
studies and human clinical trials [1,2,4–6,8]. However, this
protocol still requires complex cell preparation processes [9],
which represents a critical barrier for broad clinical applications.
Consequently, development of a scaffold for tissue engineering of
vasculature that does not require cell seeding is in development
here.
Although various types of scaffolds have been examined in this
laboratory, successful patency rates did not differ between scaffolds
with or without cell seeding (unpublished observations). Histolog-
ical observations in a previous study here suggested that tissue
regeneration was chiefly dependent on neighboring cells and not
on seeded cells [6]. Furthermore, seeded MN-BMCs contributed
as producers of cytokines, which induce cell recruitment for
constructing mature tissues, rather than differentiating into mature
vasculature components [10]. Therefore, it was concluded that
seeding of autologous cells onto a scaffold is not a promising
strategy and that it might be possible to create an iTEV with an
optimized biodegradable scaffold without cell seeding.
Although the late-term results of TEVAs are acceptable, the
problem of graft stenosis generation in some patients still exists [4].
Such stenotic changes may cause tissue regeneration disorders,
such as blood flow disturbance, thrombogenesis, or graft occlusion.
Graft stenosis was also found to occur within a few months after
implantation and a graft was never occluded or suffered from
stenosis after complete endothelial coverage (unpublished obser-
vations), suggesting that scaffold reinforcement during the
relatively early period of tissue development is essential.
The focus here was on the design of a biodegradable scaffold
with optimal mechanical properties and degradation time. It
should maintain its shape during early endothelialization after
implantation to avoid blood flow disturbances and overgrowth of
fibrotic tissue. From previous studies here, neointimal growth with
internal surface endothelialization of the scaffold occurs within a
Figure 6. Biomechanical analyses of IVC and iTEV at 2 years. A, representative P–S loop data for control scaffold and iTEV and native IVC at
2 yr; P–S loops from time-dependent strain and pressure measurements ei,pi fg , used to calculate sample elastic moduli. B, elastic moduli ratios of
iTEV to native IVC at 0 (control), 1, 2.5, 6, 12, and 24 months (n=7); significant differences between control and samples (p,0.0001 by ANOVA); ***,
p,0.001, control vs. 1 month and **, p,0.01, control vs. 2.5–24 months by Dunnett’s post hoc test. C, iTEV RS at 1, 2.5, 6, 12, and 24 months (n=7); RS
maintained by scaffold while tissue in infancy; data show iTEV elasticity not affected by time after implantation; Note, P(GA/CL) monofilament and
P(LA/CL) sponge scaffold lose strength within ,2.5 and 6 months, respectively (p=0.443 by ANOVA); NS, not significant.
doi:10.1371/journal.pone.0035760.g006
Figure 7. Protein densitometry of endothelial cells and smooth
muscle cells of the iTEV and IVC. Bar graphs of CD146 and ASMA
protein densitometry normalized by beta-actin concentrations; all
results from native IVC and iTEV samples at 2 years (n=7 each); ratios
of ASMA and CD146 to beta-actin, means 6SEM; no significant
differences (CD146, p=0.193 and ASMA, p=0.907 by unpaired
Student’s t-test); NS, not significant.
doi:10.1371/journal.pone.0035760.g007
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period, if fibrotic tissues massively proliferated, stenotic changes in
the iTEV would have been observed (unpublished observations).
Thus, a material that maintains its shape during the endothelia-
lization period is considered able to avoid graft stenosis and a
novel biodegradable scaffold was developed that was reinforced
with P(GA/CL) monofilaments on the outer surface, to maintain
iTEV shape for the initial crucial period following implantation.
These monofilaments, however, decreased in strength within a
month and then degraded within 2 months, with the P(LA/CL)
spongy scaffold concurrently but more slowly degrading in the
iTEV to create a relatively constant elasticity in the iTEV during
the tissue-remodeling process. As a result, this new P(GA/CL)
monofilament-reinforced scaffold prevented graft stenosis and
allowed complete endothelialization of the graft inner surface.
Furthermore, these iTEVs reached optimal elasticity after a
month, judged from RS values. Consequently, tissue regeneration
was also attained without complications, resulting in long-term
iTEV patency. These findings suggested that this new biodegrad-
able scaffold possessed significant potential for reducing the
incidence of graft stenosis observed in previous clinical trials.
As the mechanical properties of a scaffold are closely related to
biocompatibility, maturity, and structural integrity of grafted
materials, the iTEV elastic modulus has been evaluated [11,12].
Although mechanical tests of the excised tissue samples from
euthanized animals indicated the immediate iTEV character, it
has been impossible to determine the course of continuous changes
in the elastic modulus in vivo [2]. In the present study, a novel in vivo
system for tracking elastic moduli is proposed which uses an IVUS
and a pressure catheter for evaluating the iTEV mechanical
properties [7]. This technique enabled assessment of iTEV
elasticity changes as well as reduction of the number of animals
required. The chosen scaffold degraded and changed its elastic
moduli during tissue development and regeneration to form
mature vasculature, such that, at 1–2.5 months, when the tissue
was still in its infancy, iTEVs revealed adequate RSs and elastic
moduli ratios. At 1–2 years, after scaffolds resorption, iTEVs
showed RSs and elastic moduli ratios similar to native IVCs,
which suggested significant remodeling of iTEVs.
The IVUS images showed changes in iTEV wall characteristics
in vivo, in which neointima developed on the scaffold interior
surfaces, the internal diameter reduced in the early phase, and the
internal diameter increased, during which time the scaffold was
resorbed and tissue developed.
It is widely known that artificial grafts are reliable, stable, and in
common use throughout the world. However, concerns still
remain regarding non-biocompatibility, such as calcification [13],
thrombosis [14,15,16], and decreased diameter due to pseudo-
intimal peel formation [16,17,18]. Although an iTEV is initially an
artificial material when implanted, the scaffold resorbs over time,
allowing regeneration of ‘‘native vessels.’’
The iTEV is a promising alternative to artificial grafts,
particularly in venous positions, and have benefits, such as
avoidance of anticoagulation therapy and reductions in the
incidence of thromboembolic complications and calcification
[2,6], and the potential to remodel into an appropriate size in
response to vessel flow or a patient’s growth [5]. Thus, in the field
of congenital heart diseases, this novel strategy could provide great
benefits for children who require anatomical repair using an
artificial graft. Surgeons tend to implant oversized grafts in
pediatric patients, increasing the chance of thrombosis in the
prosthetic graft. Therefore, an ideal graft that adapts to the child’s
growth is desired, as more suitable future-sized grafts cannot be
implanted in pediatric patients. The present findings have shown
that an iTEV undergoes remodeling to meet the body’s
requirements, evidenced by changes in iTEV diameter and length
over time. Furthermore, iTEVs managed to maintain their
original features and mechanical properties, while avoiding
stenosis and calcification. All these findings supported the realistic
possibility of applying iTEVs to pediatric cardiovascular surgery.
At present, iTEVs are envisioned for use in systemic venous
reconstruction, such as modified Fontan operations (extracardiac
total cavo-pulmonary connection) and modified Warden proce-
dures for partial anomalous pulmonary venous connection. These
iTEVs are biocompatible, anti-thrombogenic, and have the
remodeling potential required by pediatric patients with congenital
heart diseases as they grow. For extended applications of iTEVs,
further studies of the scaffold under high-pressure circumstances
should be conducted.
In conclusion, an iTEV with good long-term results can be
constructed by direct implantation of this new biodegradable
scaffold. As the scaffold degraded and autologous tissue developed
in vivo, the new ‘‘regenerated’’, ‘‘reconstructed’’, and ‘‘adapted’’
vasculature possessed biocompatible characteristics, thereby
avoiding unwanted calcification. Based on the present findings,
the protocol for iTEV development can be simplified and made
more versatile. We think that this novel ‘‘Cell-Free Tissue
Engineering for Vasculature’’ can easily be applied to treatments
of patients who require surgical interventions with artificial grafts
to provide them a better quality of life.
Figure 8. Biochemical analyses of the iTEV and IVC at 2 years. A–C, elastin, hydroxyproline, and calcium contents in IVC and iTEV at 2 years;
data, means 6SEM (n=7 each); no significant differences (elastin, p=0.615 and hydroxyproline, p=0.750 by Student’s t-test; calcium, p=0.165 by the
Mann–Whitney U test); NS, not significant.
doi:10.1371/journal.pone.0035760.g008
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Ethics statement
The ethical committee of Tokyo Women’s Medical University
reviewed and approved the study protocol (Permit Number: 07-
68).
Newly developed biodegradable scaffold for cell-free
iTEV
A composite tubular scaffold has been previously developed,
consisting of polyglycolide (PGA) knitted fibers and an L-lactide
and e-caprolactone copolymer (P(LA/CL)) sponge with outer
glycolide and e-caprolactone copolymer (P(GA/CL)) monofila-
ment reinforcement. The PGA fibers and P(LA/CL) sponge were
the same as those used in previous studies to create TEVAs [1,2].
The P(GA/CL) monofilament (0.45 mm diameter) was wound
around the scaffold outer surface with a pitch of 3 mm (Fig. 1A).
As the P(GA/CL) monofilament will lose its strength within 2
months owing to non-enzymatic hydrolysis, it was used to provide
reinforcement during the crucial tissue construction period. The
new scaffold possessed 27 times higher compression strength than
previous scaffolds and was sterilized with ethylene oxide gas prior
to implantation.
Mechanical and degradation tests of biodegradable
scaffolds in vitro
Biodegradable scaffolds were cut in ,1-cm width rings and
soaked in PBS at 37uC for 0–25 weeks. For assessment, the tensile
strength (N) of sample scaffolds at 0–9 weeks were measured on a
tensiometer (EZTest, Shimadzu, Kyoto, Japan) at a crosshead
speed of 50 mm/min. The molecular weight (Mw) was determined
by gel permeation chromatography using a Shimadzu GPC-
System equipped with a pump, degasser (LC-10AT VP) at 1.0 ml/
min and a refractive index detector (RID-10A, Shimadzu). The
column was eluted with trichloromethane at 1.0 ml/min at 40uC
and calibrated with polystyrene standards over an Mw range of
4,000–1,600,000 daltons.
Animal experiments
Thirteen healthy adult female beagles (NARC, Tomisato,
Japan) with a mean weight of 9.3 kg (7.0–11.5 kg) were obtained
for this study, with six animals euthanized for histological
examinations at 1 (n=3) and 3 (n=3) months, and seven animals
euthanized at 24 months for histological and biochemical analyses.
For surgeries, animals were anesthetized with pentobarbital
(1 mg/kg body weight) and atropine sulfate (0.08 mg/kg body
weight), with heparin (500 U/kg body weight) administered
intravenously for anticoagulation during anastomoses. Each
scaffold (8 mm diameter and 2–3 cm long) was implanted into
the IVC, as described previously [2,6], and the animals followed
by IVUS until 24 months (1 (n=11), 2.5 (n=11), 6 (n=8), 12
(n=7), and 24 (n=7) months). Aspirin (2 mg) was orally
administered for the first month after surgery as an anticoagulation
therapy and subsequently maintained without anticoagulants until
euthanasia.
After dissection, the iTEV length was measured directly
between the two suture lines and the iTEV then longitudinally
dissected to allow histological and biochemical analyses. For each
assay, samples of native IVC and iTEV were dissected, rinsed with
PBS, and stored at 220uC until analysis.
Histological examination
Longitudinally incised iTEV and native IVC samples as controls
were fixed in 4% paraformaldehyde in pH 7.0 PBS, embedded in
paraffin, and sectioned at 4–5 mm. Some sections were subjected
to hematoxylin and eosin (H&E), Masson’s trichrome, Victoria
blue–van Gieson, or modified von Kossa staining, as previously
described [2,6]. Immunostaining of other sections was performed
with antibodies against factor VIII (1:1000) and ASMA (clone
1A4; 1:1000; Dako Japan Inc., Tokyo, Japan). iTEV wall
thicknesses were measured at 10 different sites in these sections
and all histological examinations and measurements performed
using a microscope (Biozero BZ-8000; Keyence Corp., Osaka,
Japan) and accompanying analytical software (BZ-Analyzer;
Keyence Corp.).
Angiography and biomechanical analyses using IVUS
Subject animals were anesthetized using the protocol described
above and placed in sterilized conditions for femoral vein
dissection. An 8-Fr long catheter sheath (Terumo Corp., Tokyo,
Japan) was placed through the femoral vein adjacent to the IVC,
close to the diaphragm. An X-ray fluoroscope was used to identify
sheath and catheter locations and for digital angiography.
Approximately 5 ml of angiographic agent was injected to
evaluate iTEV features and to measure the smallest iTEV internal
diameter during the regeneration process and in native IVCs of
control dogs. Next, a 2-Fr Millar Mikro-Tip catheter pressure
transducer (Millar Instruments Inc., Houston, TX) and a 2.5-Fr
IVUS (Terumo Corp.) were inserted through the long catheter
sheath. Simultaneously, a Millar Mikro-Tip catheter was used to
measure the pressure gradient between iTEV proximal and distal
sites.
The elastic moduli of iTEVs and native IVCs were analyzed
based on the P-S loops obtained using synchronized ultrasonic B-
mode images and pressure signals recorded in the lumen, acquired
using ultrasound and pressure sensor catheters [7]. Vessel wall
deformation induced by circumferential stress was analyzed using
successive ultrasonic B-mode images reconstructed using RF data.
Repeated imaging of the lumen on ultrasonic B-mode images
enabled calculation of the time-dependent luminal circumferential
length li fg(i~0?N{1; N, number of B-mode images). When
the li fg in the initial frame is expressed by {l0}, the
circumferential strain ei on the i-th frame can be calculated as
follows:
ei~
li{l0
l0
Plotting of the time-dependent pressure {pi} and circumferen-
tial strain {ei} values allowed calculation of the P-S loop and the
dynamics of the iTEV wall and native IVC. The elastic modulus
(m) was calculated using the measured parameters that make up
the P-S loop ei,pi fg as follows:
m~
1
N{1
X N{2
i~0
piz1{pi
el
iz1{el
i
Using the elastic moduli of the iTEVs and IVCs, the RS was
calculated by comparing the elastic moduli of native IVCs with
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degree of iTEV regeneration:
RS~100|f1{(mN{mT)=(mND{mTD)g(%)
where mN and mT indicate the elastic moduli of native IVC and
iTEV at any time, respectively, and mN0 and mT0 indicate the
elastic moduli of native IVC and iTEV immediately after
implantation, respectively. In other words, the difference between
the elastic moduli of iTEV and native IVC at any time was
normalized by that observed immediately after implantation.
Based on this formula, RSs of 0% and 100% indicated incomplete
and complete regeneration, respectively.
Biochemical analyses of protein, elastin, hydroxyproline,
and calcium content
After thawing, iTEV and native IVC samples were weighed and
homogenized at a 1/20 (w/v) ratio of tissue to Tissue Protein
Extraction Reagent (Thermo Fisher Scientific Inc., Rockford, IL)
for protein extraction, and the total protein content determined
using the Bradford assay. Samples of the denatured proteins, at
15 mg per lane, were separated in 4–12% polyacrylamide gels
(NuPAGER NovexH Bis-Tris [Bis (2-hydroxyethyl) imino-Tris
(hydroxymethyl) methane-HCl] Midi Gels; Invitrogen, Carlsbad,
CA) and transferred to polyvinylidene difluoride membranes using
an iBLOT dry blotting system (Invitrogen). As primary antibodies,
an anti-ASMA antibody (1:1000, clone 1A4; Dako) and an anti-
CD146 antibody (1:1000; Epitomics, Inc., Burlingame, CA) were
used to detect endothelial cell proteins in iTEVs, with an anti-
human beta-actin antibody (1:2000; Abcam, Cambridge, MA)
used as an internal control. A WesternBreezeH Chemilumines-
cence Immunodetection Kit and a BenchPro
TM 4100 system
(Invitrogen) were used for detection of antigen-antibody complexes
immobilized on polyvinylidene difluoride membranes, according
to the manufacturer’s protocol. After membrane enhancement by
treatment with the kit chemiluminescent reagent, chemilumines-
cence images were acquired using a cooled CCD camera (LAS-
3000 Mini; Fujifilm Corp., Tokyo, Japan) and analyzed using
image analysis software (MultiGauge; Fujifilm Corp.).
A commercially available elastin assay kit (Fastin Elastin Assay
Kit; Biocolor, Ltd., Belfast, Northern Ireland) was used to quantify
the elastin content of iTEV and native IVC samples. Insoluble
tissue elastin was solubilized by hot oxalic acid treatment,
precipitated, and mixed with the Fastin dye reagent. The
elastin–dye complex was collected by centrifugation, dye bound
to the elastin pellet solubilized with the Destain reagent, and the
recovered dye concentration measured at 513 nm.
Sample hydroxyproline contents were measured by high-
performance liquid chromatography (HPLC). In preparation,
tissue samples were weighed and digested with 12 N HCl for 24 h,
the resulting suspensions hydrolyzed with 0.5 ml of 12 N HCl for
20 h at 100uC, and after neutralization and centrifugation, a 0.1-
ml aliquot of each supernatant was mixed with 1.5 ml of 0.3 N
lithium hydroxide solution for analysis by HPLC.
The calcium concentrations of the tissue samples were
determined using a Zeeman polarized atomic absorption spectro-
photometer (Model Z-6100; Hitachi Co., Ltd., Tokyo, Japan).
Tissue samples were weighed and digested with nitric acid and
concentrated hydrogen peroxide (ratio, 4/1) and a model
MLS1200 microwave system (Milestone Inc., Monroe, CT) was
used to achieve sample decomposition. Subsequently, 25 mlo f
each sample was added to 2 ml of 10% lanthanum chloride and
the calcium content measured by reference to a standard calcium
solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Statistical analysis
An unpaired Student’s t-test or the Mann–Whitney U test was
used to compare the results from the control and time groups
depending on each group’s data variance. One-way analysis of
variance (ANOVA) followed by Dunnett’s post hoc analyses or the
Kruskal–Wallis test were used when the variances were not
appropriate. All data were expressed as means 6SEM, and
probability values of p,0.05 considered to indicate statistical
significance. IBM SPSS Statistics 19 (IBM Japan, Ltd., Tokyo,
Japan) was used for statistical analyses.
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